Skip to main content
. 2016 Feb 21;7(11):13139–13152. doi: 10.18632/oncotarget.7545

Figure 1. Relative miR-194 expression in NSCLC tissue and its clinical significance.

Figure 1

(A) Relative expression of miR-194 expression in NSCLC tissue (n = 64) and in paired adjacent non-cancerous tissues (n = 64). (B) Relative expression of miR-194 expression in NSCLC patients with stage I–II disease and with stage III–IV disease. (C) Kaplan-Meier analysis of overall survival in patients with tumors that express high levels of miR-194 versus patients with tumors that express low levels of miR-194. (D) The expression levels of miR-194 in multiple NSCLC cell lines relative to the benign 16HBE cell line were assessed by qRT-PCR. MiR-194 expression was normalized to U6 expression. **P < 0.01.